SCHEMBL20045401

SCHEMBL20045401

CC(Oc1ccc(F)cc1)C(=O)Oc1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 1/20 0.53
PPARG P37231 1/20 0.50
PPARA Q07869 1/20 0.50
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
POLB P06746 2/20 0.45
EPHX2 P34913 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23356457 0.92 CYP1A2 (0.54) TDP1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL9363151 0.87 CYP1A2 (0.50) PPARGPPARACYP1A2CYP2C9CYP2C19
SCHEMBL10175713 0.86 PPARG (0.50) TDP1ALDH1A1PPARGPPARACYP1A2
SCHEMBL11646451 0.82 PPARA (0.53) TDP1PPARGPPARACYP1A2CYP2C9
SCHEMBL11609867 0.80 CYP1A2 (0.55) ALDH1A1PPARGPPARACYP1A2CYP2C9
SCHEMBL18331157 0.80 HTR2A (0.53) TDP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL23368102 0.80 HTR2A (0.53) TDP1ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL9285601 0.78 MEN1 (0.58) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL18331472 0.78 MEN1 (0.58) ALDH1A1CYP1A2CYP2C9CYP2C19POLB
SCHEMBL5108544 0.78 ALDH1A1 (0.65) TDP1ALDH1A1POLBSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11730714-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2023-08-22 US disclosed
US-11730714-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2023-08-22 US disclosed
US-11147788-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2021-10-19 US disclosed
EP-3307262-B1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA AS (DK) 2021-05-19 EP disclosed
US-10934244-B2 Compounds for use in treating neuromuscular disorders NMD PHARMA A/S (DK) 2021-03-02 US disclosed
US-10385028-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2019-08-20 US disclosed
US-20190185409-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA APS (DK) 2019-06-20 US disclosed
US-20190183834-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA A/S (DK) 2019-06-20 US disclosed
US-20190183833-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA APS 2019-06-20 US disclosed
US-20190185437-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA APS (DK) 2019-06-20 US disclosed
US-20190183812-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA A/S (DK) 2019-06-20 US disclosed
US-20190183863-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA A/S (DK) 2019-06-20 US disclosed
US-20180099920-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA APS (DK) 2018-04-12 US disclosed
US-20180099920-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS NMD PHARMA APS (DK) 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11730714-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 TDP1 277/4885ALDH1A1 1343/4885PPARG 3332/4885
US-10934244-B2 Compounds for use in treating neuromuscular disorders CPT1B, CLCN2, TNNC1 TDP1 1056/4885ALDH1A1 1498/4885PPARG 2105/4885
US-20190183834-A1 Compounds For The Treatment Of Neuromuscular Disorders RYR1, CACNB1, RYR2 TDP1 277/4885ALDH1A1 1343/4885PPARG 3332/4885
US-20190185409-A1 Compounds For The Treatment Of Neuromuscular Disorders CPT1B, CLCN2, CACNB1 TDP1 990/4885ALDH1A1 829/4885PPARG 997/4885
US-20180099920-A1 COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS CPT1B, CLCN2, TNNC1 TDP1 1056/4885ALDH1A1 1498/4885PPARG 2105/4885
US-20190183812-A1 Compounds For The Treatment Of Neuromuscular Disorders RYR1, CACNB1, RYR2 TDP1 277/4885ALDH1A1 1343/4885PPARG 3332/4885
US-11147788-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 TDP1 277/4885ALDH1A1 1343/4885PPARG 3332/4885
US-10385028-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 TDP1 277/4885ALDH1A1 1343/4885PPARG 3332/4885
US-20190183863-A1 Compounds For The Treatment Of Neuromuscular Disorders RYR1, CACNB1, RYR2 TDP1 277/4885ALDH1A1 1343/4885PPARG 3332/4885
US-20190185437-A1 Compounds For The Treatment Of Neuromuscular Disorders CLCN2, SCN1B, CACNB1 TDP1 1002/4885ALDH1A1 1891/4885PPARG 3152/4885
US-20190183833-A1 Compounds For The Treatment Of Neuromuscular Disorders RYR1, CACNB1, RYR2 TDP1 277/4885ALDH1A1 1343/4885PPARG 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.